Lung Repair Regenerative Research
A cellular and signaling view of lung tissue regeneration.
Lung tissue regeneration is among the most consequential and under-served conversations in regenerative medicine. The alveolar architecture that performs gas exchange is delicate, the consequences of damage from smoking, viral infection, environmental fibrosis, or autoimmune attack are typically progressive, and conventional pharmacotherapy is largely palliative or anti-inflammatory rather than repair-directed. Research observes anti-inflammatory and tissue-remodeling effects from mesenchymal-stem-cell (MSC) therapy and from MSC-derived exosomes in animal models of pulmonary fibrosis, COPD, and acute lung injury. Human clinical trials are progressing through phase I and phase II for several indications, with results that are encouraging but still preliminary. Functional nutrition — N-acetyl cysteine, omega-3 EPA/DHA, vitamin D status, specific amino-acid support — plays an adjunctive role in supporting endogenous repair capacity. None of this is curative for end-stage disease, and we are careful not to frame it as such.
Academic frame first, clinical translation cautiously.
The MMC Anti-Aging Research Institute treats lung repair as a research direction. We participate through academic collaboration with UBC and SFU partners and Shanghai Xinuo Shenzhou (founded December 2021), with periodic involvement in international conferences and review papers. Dr. Jiang's team evaluates emerging clinical protocols on their evidence and on the appropriateness for the Canadian regulatory and member context. We do not enroll members into experimental lung-repair therapies that have not cleared appropriate ethics-board review and regulatory pathway. Where clinical protocols do mature to a compliant pathway, we will inform members through documented channels and refer to appropriate partner clinics for delivery — not deliver it ourselves outside of the research framework.
What we can do today for lung health.
While the regenerative protocol matures, Longevity Club members with lung-health concerns receive coordinated assessment through what we can do today: spirometry (in MMC Exams), DLCO when indicated, low-dose chest CT screening for high-risk members, vitamin D and inflammation profile, comprehensive nutritional review with NAC and omega-3 support where appropriate, and respiratory physiotherapy referral. For members with established pulmonary fibrosis, COPD, or Long COVID, we coordinate with respirology specialists at Vancouver General and partner clinics. The member-facing distinction is clear: research direction stays academic; standard-of-care lung health stays clinical. Members get visibility into both, with no blurring of lines.
- 01
Research Direction
Exosome + MSC + functional nutrition lung-repair exploration — animal model and early-phase human trials.
- 02
Academic Partners
UBC, SFU, Shanghai Xinuo Shenzhou (founded December 2021) collaboration.
- 03
Indications Studied
Pulmonary fibrosis, COPD, post-COVID syndromes, acute lung injury — research stage.
- 04
Clinical Protocol
Under development by Dr. Jiang's team; specific indications and enrollment rules to follow.
- 05
Standard-Care Lung Health
Spirometry, DLCO, low-dose chest CT, vitamin D and inflammation panel, NAC and omega-3 support — available today.
- 06
Respirology Referral
Coordination with Vancouver General and partner-clinic respirology for established disease.
- 07
Member Updates
Documented-channel notice if and when research enrollment opens to members.
- 08
Research Boundary
Not a clinical service today; no medical commitment to members.
Frequently Asked
Can I enroll in lung-repair therapy at MMC today?
No. The lung-repair direction is academic research, not a clinical service. We do not enroll members into experimental therapies that have not cleared appropriate ethics-board review and regulatory pathway. We are deliberate about that boundary.
I have Long COVID — what can MMC do for me today?
Today we can coordinate the standard-care evaluation: respiratory function tests, inflammation profile, vitamin D status, mitochondrial-support nutrition, NAC and omega-3 supplementation where appropriate, sleep and autonomic-function evaluation, and referral to specialty Long COVID clinics. The regenerative direction is research; the standard-care pathway is what we can offer clinically.
Will MSC therapy be available in Canada soon?
MSC therapy for specific indications (graft-vs-host disease, certain pediatric conditions) is approved in some jurisdictions. For pulmonary indications it remains research stage in Canada. We do not predict timing — clinical translation depends on multi-year trial readouts that are still in progress.